LCZ696在心血管疾病中的研究进展

Research Progress of LCZ696 in Cardiovascular Diseases

沙库巴曲/缬沙坦(LCZ696)是一种新的治疗心血管疾病的药物,它将血管紧张素受体阻滞剂缬沙坦和脑啡肽酶抑制剂前药沙库巴曲按1∶1比例结合在钠超分子复合物中。目前,我国高血压的控制率并不是很理想,对于心力衰竭也没有有效治疗药物。而LCZ696通过抑制脑啡肽酶和血管紧张素Ⅱ受体,不仅能升高利钠肽水平,利钠肽具有利尿、抗增殖、抗心肌肥厚等作用,还能够降低血管紧张素Ⅱ1型受体活性,抑制血管收缩、交感神经兴奋,使醛固酮分泌减少,抑制炎症反应和氧化应激。因此,LCZ696对心血管疾病(心力衰竭和高血压)具有一定的作用。但未来仍需要更大型的临床研究来证实其有效性及安全性。

Sacubitril/valsartan(LCZ696)is a new drug for the treatment of cardiovascular diseases.It binds the angiotensin receptor blocker valsartan and enkephalinase inhibitor sacubitril in a 1∶1 scale in sodium supramolecular complexes.At present,the control rate of hypertension in China is not ideal,and there is no effective medicine for the treatment of heart failure.However,LCZ696 not only can increase the level of natriuretic peptide by inhibiting enkephalinase and angiotensinⅡreceptor,which has diuresis,anti-proliferation,anti-myocardial hypertrophy effects,but also can reduce the activity of angiotensinⅡtype 1 receptor,inhibit vasoconstriction,sympathetic excitement,reduce aldosterone secretion,and inhibit inflammatory response and oxidative stress.Therefore,LCZ696 has a certain effect on cardiovascular diseases(heart failure and hypertension).But larger clinical studies are needed to confirm its efficacy and safety in the future.